Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation

  • Tristán-Noguero, Alba
  • Fernández-Carasa, Irene
  • Calatayud, Carles
  • Bermejo-Casadesús, Cristina
  • Pons-Espinal, Meritxell
  • Colini Baldeschi, Arianna
  • Campa, Leticia
  • Artigas, Francesc
  • Bortolozzi, Analía
  • Domingo-Jiménez, Rosario
  • Ibáñez, Salvador
  • Pineda, Mercè
  • Artuch, Rafael
  • Raya, Ángel
  • García-Cazorla, Àngels
  • Consiglio, Antonella
Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early-onset Parkinsonism. Affected children present with either a severe form that does not respond to L-Dopa treatment (THD-B) or a milder L-Dopa responsive form (THD-A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control-DAn from healthy individuals and gene-corrected isogenic controls. Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control-iPSC. Treatment of THD-iPSC-DAn with L-Dopa rescued the neuronal defects and disease phenotype only in THDA-DAn. Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC-based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management., The authors are indebted to the THD patients who have participated in this study. The authors thank Bernd Kuebler and Begoña Aran from the P-CMR[C] Stem Cell Bank, for generating the THD iPSCs. We would like to thank Marcia Triunfol and João Mello-Vieira at Publicase for their help with this manuscript. Research from the authors' laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL) and ERC 2020-PoC (957581 NeurAntigen), the Spanish Ministry of Economy and Competitiveness-MINECO (PID2019-108792GB-I00, PID2019-105136RB-100, PID2021-123925OB-I00, PDC2021-121051-I00 and RTI2018-095377-B-100), supported by MCIN/AEI/10.13039/501100011033 and “NextGenerationEU/PRTR”, Instituto de Salud Carlos III-ISCIII/ and “Fondo Europeo de desarrollo regional” (FEDER) (Red de Terapia Celular - TerCel RD16/0011/0024, FIS PI15/01082, P118/00111), Agencia Estatal de Investigación-AEI (Unidad de Excelencia María de Maeztu CEX2018-000792-M), AGAUR (2017-SGR-899 and 2017-SGR-1061), Fundació la Marató de TV3 (202012-31 and 202012-32) and CERCA Programme/Generalitat de Catalunya. CC was partially supported by predoctoral fellowship (FPU12/03332) from the Spanish Ministry of Education (MEC). AT-N was partially supported by a PFIS pre-doctoral fellowship (FI14/00641) from the Instituto de Salud Carlos III-ISCIII and 2018BR-IRSJD-CdTorres from Sant Joan de Déu Hospital. AC is a recipient of an ICREA “Academia” Award (Generalitat de Catalunya)., Peer reviewed